• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

虚拟阿尔茨海默病生物标志物披露的可行性:一项观察性队列研究的结果

Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.

作者信息

Erickson Claire M, Chin Nathaniel A, Rosario Hannah L, Peterson Amanda, Johnson Sterling C, Clark Lindsay R

机构信息

Department of Medical Ethics and Health Policy University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA.

Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.

出版信息

Alzheimers Dement (N Y). 2023 Jul 29;9(3):e12413. doi: 10.1002/trc2.12413. eCollection 2023 Jul-Sep.

DOI:10.1002/trc2.12413
PMID:37521522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10382796/
Abstract

INTRODUCTION

Increased availability of Alzheimer's disease (AD) biomarker tests provides older adults with opportunities to seek out and learn results. We evaluated the feasibility of virtually returning AD biomarker results.

METHODS

Trained study clinicians disclosed amyloid positron emission tomography (PET) results and provided dementia risk-reduction counseling via televideo to cognitively unimpaired participants already enrolled in AD research ( = 99; mean age ± SD: 72.0 ± 4.8; 67% women; 95% White; 28% amyloid elevated).

RESULTS

Our study demonstrated acceptable levels of retention (93%), compliance (98%), adherence (98%), clinician competence (97%), education comprehension (quiz scores 14/15), and virtual visit functionality (rating 9.4/10). Depression, anxiety, and suicidality remained low and did not differ by amyloid result.

DISCUSSION

Virtual return of amyloid PET results to cognitively unimpaired research participants is feasible and does not result in increased psychological symptoms. Technological barriers for some participants highlight the need for flexibility. These findings support the use of televideo in AD biomarker disclosure, although our study sample and design have important limitations for generalizability.

摘要

引言

阿尔茨海默病(AD)生物标志物检测的可及性增加,为老年人提供了获取和了解检测结果的机会。我们评估了虚拟反馈AD生物标志物结果的可行性。

方法

训练有素的研究临床医生通过视频向已参与AD研究的认知未受损参与者披露淀粉样蛋白正电子发射断层扫描(PET)结果,并提供痴呆症风险降低咨询(n = 99;平均年龄±标准差:72.0±4.8;67%为女性;95%为白人;28%淀粉样蛋白升高)。

结果

我们的研究显示出可接受的保留率(93%)、依从性(98%)、坚持性(98%)、临床医生能力(97%)、教育理解度(测验分数14/15)和虚拟就诊功能(评分9.4/10)。抑郁、焦虑和自杀倾向仍然较低,且不因淀粉样蛋白结果而异。

讨论

向认知未受损的研究参与者虚拟反馈淀粉样蛋白PET结果是可行的,且不会导致心理症状增加。一些参与者面临的技术障碍凸显了灵活性的必要性。这些发现支持在AD生物标志物披露中使用视频,尽管我们的研究样本和设计在普遍性方面存在重要局限性。

相似文献

1
Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.虚拟阿尔茨海默病生物标志物披露的可行性:一项观察性队列研究的结果
Alzheimers Dement (N Y). 2023 Jul 29;9(3):e12413. doi: 10.1002/trc2.12413. eCollection 2023 Jul-Sep.
2
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.向认知未受损的研究参与者传达阿尔茨海默病生物标志物检测结果:满意度、效用及对研究态度的影响
Alzheimers Dement (N Y). 2024 Jun 14;10(2):e12483. doi: 10.1002/trc2.12483. eCollection 2024 Apr-Jun.
3
Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.告知阿尔茨海默病生物标志物信息:在淀粉样蛋白检测结果披露期间,认知正常成年人的关注点和理解。
J Prev Alzheimers Dis. 2024;11(6):1572-1580. doi: 10.14283/jpad.2024.151.
4
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial.在一项临床前阿尔茨海默病试验中,淀粉样蛋白状态升高的披露与长期自杀倾向无关。
Alzheimers Dement. 2025 Feb;21(2):e14623. doi: 10.1002/alz.14623.
5
Psychosocial implications of learning amyloid PET results in an observational cohort.学习淀粉样 PET 结果的心理社会影响:一项观察性队列研究。
Alzheimers Dement. 2024 Sep;20(9):6579-6589. doi: 10.1002/alz.14153. Epub 2024 Aug 11.
6
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.淀粉样蛋白和 Tau 预测认知和功能下降在认知正常的老年人:来自 A4 和 LEARN 研究的纵向数据。
J Prev Alzheimers Dis. 2024;11(4):802-813. doi: 10.14283/jpad.2024.122.
7
Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.在一项临床前阿尔茨海默病试验中对淀粉样蛋白成像的观点和看法。
J Prev Alzheimers Dis. 2024;11(6):1563-1571. doi: 10.14283/jpad.2024.157.
8
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.全球截断随机试验中认知未受损个体对阿尔茨海默病生物标志物披露的即时反应
Neurol Clin Pract. 2024 Apr;14(2):e200265. doi: 10.1212/CPJ.0000000000200265. Epub 2024 Jan 12.
9
Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.家庭成员对认知正常的老年人淀粉样蛋白-β PET 扫描结果的学习的看法。
J Am Geriatr Soc. 2021 Nov;69(11):3203-3211. doi: 10.1111/jgs.17362. Epub 2021 Jul 12.
10
Emotional distress following amyloid PET result disclosure: Heightened among those with cognitive symptoms.淀粉样蛋白PET结果披露后的情绪困扰:认知症状患者中更为严重。
Alzheimers Dement. 2025 Apr;21(4):e70121. doi: 10.1002/alz.70121.

引用本文的文献

1
Communicating the risk of dementia: a scoping review.痴呆症风险的沟通:一项范围综述
BMJ Neurol Open. 2025 Jul 22;7(2):e001138. doi: 10.1136/bmjno-2025-001138. eCollection 2025.
2
Return of research results across the Alzheimer's Disease Research Centers network.阿尔茨海默病研究中心网络的研究结果反馈
Alzheimers Dement. 2025 Jun;21(6):e70418. doi: 10.1002/alz.70418.
3
Genetic and biomarker disclosure process in a memory and aging study.记忆与衰老研究中的基因和生物标志物披露过程。

本文引用的文献

1
Disclosing Individual Results in Dementia Research: A Proposed Study Participant's Bill of Rights.披露痴呆症研究中的个体结果:研究参与者权利法案草案。
J Alzheimers Dis. 2022;90(3):945-952. doi: 10.3233/JAD-220810.
2
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.临床前阿尔茨海默病生物标志物披露对美国政策和社会的影响。
Alzheimers Dement (Amst). 2022 Aug 25;14(1):e12339. doi: 10.1002/dad2.12339. eCollection 2022.
3
Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).
J Alzheimers Dis. 2025 Mar;104(2):312-318. doi: 10.1177/13872877251315957. Epub 2025 Feb 9.
4
Paving the way for Alzheimer's disease blood-based biomarkers in primary care.为初级保健中基于血液的阿尔茨海默病生物标志物铺平道路。
Alzheimers Dement. 2025 Jan;21(1):e14203. doi: 10.1002/alz.14203. Epub 2024 Dec 30.
5
Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.预测性阿尔茨海默病诊断中的咨询与信息披露实践:一项范围综述
Alzheimers Dement. 2024 Dec;20(12):8910-8936. doi: 10.1002/alz.14365. Epub 2024 Nov 19.
6
Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.告知阿尔茨海默病生物标志物信息:在淀粉样蛋白检测结果披露期间,认知正常成年人的关注点和理解。
J Prev Alzheimers Dis. 2024;11(6):1572-1580. doi: 10.14283/jpad.2024.151.
7
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
8
Psychosocial implications of learning amyloid PET results in an observational cohort.学习淀粉样 PET 结果的心理社会影响:一项观察性队列研究。
Alzheimers Dement. 2024 Sep;20(9):6579-6589. doi: 10.1002/alz.14153. Epub 2024 Aug 11.
9
Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.淀粉样蛋白 PET 披露在主观认知下降中的应用:患者随时间的体验。
Alzheimers Dement. 2024 Sep;20(9):6556-6565. doi: 10.1002/alz.14148. Epub 2024 Aug 1.
10
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.向认知未受损的研究参与者传达阿尔茨海默病生物标志物检测结果:满意度、效用及对研究态度的影响
Alzheimers Dement (N Y). 2024 Jun 14;10(2):e12483. doi: 10.1002/trc2.12483. eCollection 2024 Apr-Jun.
向认知正常的老年个体披露阿尔茨海默病的遗传风险:来自载脂蛋白 E 检测知识和反应研究(SOKRATES II)的结果。
J Alzheimers Dis. 2021;84(3):1015-1028. doi: 10.3233/JAD-210675.
4
Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.认知正常的老年人群进行淀粉样蛋白成像的原因。
Ann Clin Transl Neurol. 2021 Aug;8(8):1646-1655. doi: 10.1002/acn3.51414. Epub 2021 Jul 6.
5
A Teleneuropsychology Protocol for the Cognitive Assessment of Older Adults During COVID-19.一种用于在2019冠状病毒病期间对老年人进行认知评估的远程神经心理学方案。
Front Psychol. 2021 May 13;12:651136. doi: 10.3389/fpsyg.2021.651136. eCollection 2021.
6
Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences.临床前阿尔茨海默病生物标志物的虚拟披露:初步经验
J Am Geriatr Soc. 2021 Jul;69(7):2044-2047. doi: 10.1111/jgs.17184. Epub 2021 May 7.
7
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.临床前阿尔茨海默病生物标志物结果在研究和临床环境中的披露:为何披露、如何披露以及我们仍需了解的内容。
Alzheimers Dement (Amst). 2021 Feb 20;13(1):e12150. doi: 10.1002/dad2.12150. eCollection 2021.
8
The Future Is P-Tau-Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests.未来是基于磷酸化tau蛋白的直接面向消费者的阿尔茨海默病血液检测。
JAMA Neurol. 2021 Apr 1;78(4):379-380. doi: 10.1001/jamaneurol.2020.4835.
9
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.向无认知障碍的研究参与者披露淀粉样蛋白成像结果的短期心理结果。
JAMA Neurol. 2020 Dec 1;77(12):1504-1513. doi: 10.1001/jamaneurol.2020.2734.
10
Guidelines for reporting non-randomised pilot and feasibility studies.非随机对照预试验和可行性研究报告指南
Pilot Feasibility Stud. 2019 Oct 6;5:114. doi: 10.1186/s40814-019-0499-1. eCollection 2019.